Lung Cancer News and Research

Latest Lung Cancer News and Research

Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer

Boehringer Ingelheim today announced the initiation of two phase II studies, 1200.89 and LUX-Breast 2, evaluating afatinib in patients with metastatic breast cancer, who have an overexpression of the erbB2 (HER2) protein, so called HER2-positive patients. Afatinib is an irreversible ErbB Family Blocker, which binds to all erbB-family kinases including erbB2.

29 Aug 2011

Pfizer's Xalkori receives FDA approval to treat late-stage NSCLC patients with abnormal ALK gene

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene.

29 Aug 2011

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

The 2011 Annual Meeting & OTO EXPO of the American Academy of Otolaryngology - Head and Neck Surgery Foundation (AAO-HNSF), the largest meeting of ear, nose, and throat doctors in the world, will convene September 11-14, 2011, in San Francisco, CA.

29 Aug 2011

LUNGevity Foundation applauds FDA's recent approval of XALKORI lung cancer drug

LUNGevity Foundation applauds the US Food and Drug Administration's (FDA) recent approval of XALKORI (crizotinib) to treat lung cancer. The drug, introduced by Pfizer, Inc. showed such promise in early trials that it was given "fast track" status by the FDA.

29 Aug 2011

FDA approves Abbott's Vysis ALK FISH test for NSCLC therapy selection

Abbott today announced it has received approval from the U.S. Food and Drug Administration (FDA) for a new molecular diagnostic test designed to detect rearrangements of the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer.

29 Aug 2011

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XALKORI (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test.

29 Aug 2011

Early-morning cigarette smokers more likely to develop lung, head and neck cancers

Two new studies have found that smokers who tend to take their first cigarette soon after they wake up in the morning may have a higher risk of developing lung and head and neck cancers than smokers who refrain from lighting up right away.

26 Aug 2011

MDxHealth first half 2011 commercial revenues increase 19%

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, announced today its 2011 half-year results.

25 Aug 2011

Sarcoma Oncology Center, Aethlon Medical to study ex vivo effectiveness of Hemopurifier

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has entered into an agreement with the Sarcoma Oncology Center to study the ex vivo effectiveness of the Aethlon Hemopurifier to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients.

24 Aug 2011

Dogs ‘sniff’ out early lung cancer accurately

According to a new study in the European Respiratory Journal dogs are better at sniffing out the early markers of lung cancer than the latest medical technologies at our disposal.

23 Aug 2011

KU professor to create patient-friendly lung cancer treatment

A Kansas State University professor is trying to create a patient-friendly treatment to help the more than 220,000 people who are diagnosed with lung cancer each year.

23 Aug 2011

Helsinn begins enrollment in anamorelin Phase III trial for NSCLC-associated anorexia/cachexia

Helsinn, a Swiss-based pharmaceutical company, announced today that its US subsidiary, Helsinn Therapeutics, has enrolled the first patient in the company's pivotal Phase III clinical program of anamorelin HCl for the treatment of anorexia/cachexia in patients with advanced non-small cell lung cancer.

23 Aug 2011

IsoRay Cs-131 mesh brachytherapy with da Vinci Robot for lung cancer treatment gains momentum

IsoRay, Inc. said today that a growing number of hospitals and medical treatment centers are adopting its proprietary mesh Cesium-131 (Cs-131) brachytherapy seeds (internal radiation therapy) for use in conjunction with the da Vinci® Surgical System to treat early stage lung cancer patients. One of the most recent adopters is Georgia's Archbold Memorial Hospital.

23 Aug 2011

Johns Hopkins establishes Center for Personalized Cancer Medicine with Commonwealth Foundation gift

A $30 million gift from the Commonwealth Foundation for Cancer Research has enabled the Johns Hopkins Kimmel Cancer Center to establish a Center for Personalized Cancer Medicine. The gift from the Richmond, VA- based foundation, will be used to support research and the development of new technologies that pinpoint the novel genetic characteristics of each patient's cancer.

22 Aug 2011

High cigarette price, economic factors appear to reduce smoking rates among African-American youth

A new report in the American Journal of Public Health suggests that increasing cigarette prices combined with other social and economic factors appear to be behind the steep decline in smoking rates among African-American youth that occurred between 1970s and the mid-1990s.

20 Aug 2011

Scientists shed light on the dark secret of Queen Hatshepsut's deadly medication

The corpus delicti is a plain flacon from among the possessions of Pharaoh Hatshepsut, who lived around 1450 B.C., which is on exhibit in the permanent collection of the Egyptian Museum of the University of Bonn. For three and a half millennia, the vessel may have held a deadly secret. This is what the Head of the collection, Michael H-veler-M-ller and Dr. Helmut Wiedenfeld from the university's Pharmacology Institute just discovered.

20 Aug 2011

Scientists turn drug-disease match makers

In a new medical breakthrough American researchers have devised a drug-disease matchmaking program that mines databases for potentially useful new treatment combinations and have actually turned up two so far, said a study on Wednesday.

18 Aug 2011

Lighter smokers with two high-risk gene variations more likely to develop lung cancer

Smokers with variations in two specific genes have a greater risk of smoking more cigarettes, becoming more dependent on nicotine and developing lung cancer, a new study from the Centre for Addiction and Mental Health (CAMH) shows.

18 Aug 2011

EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review

Pfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer's regulatory submissions for review of two investigational compounds - crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC); and bosutinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.

18 Aug 2011

New research: Sniffer dogs can reliably identify lung cancer

Sniffer dogs could be used for the early detection of lung cancer, according to new research published in the European Respiratory Journal.

18 Aug 2011

Lung Cancer News and Research

Latest Lung Cancer News and Research

Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer

Pfizer's Xalkori receives FDA approval to treat late-stage NSCLC patients with abnormal ALK gene

AAO-HNSF's 2011 Annual Meeting & OTO EXPO to convene in San Francisco

LUNGevity Foundation applauds FDA's recent approval of XALKORI lung cancer drug

FDA approves Abbott's Vysis ALK FISH test for NSCLC therapy selection

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Early-morning cigarette smokers more likely to develop lung, head and neck cancers

MDxHealth first half 2011 commercial revenues increase 19%

Sarcoma Oncology Center, Aethlon Medical to study ex vivo effectiveness of Hemopurifier

Dogs ‘sniff’ out early lung cancer accurately

KU professor to create patient-friendly lung cancer treatment

Helsinn begins enrollment in anamorelin Phase III trial for NSCLC-associated anorexia/cachexia

IsoRay Cs-131 mesh brachytherapy with da Vinci Robot for lung cancer treatment gains momentum

Johns Hopkins establishes Center for Personalized Cancer Medicine with Commonwealth Foundation gift

High cigarette price, economic factors appear to reduce smoking rates among African-American youth

Scientists shed light on the dark secret of Queen Hatshepsut's deadly medication

Scientists turn drug-disease match makers

Lighter smokers with two high-risk gene variations more likely to develop lung cancer

EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review

New research: Sniffer dogs can reliably identify lung cancer

The ultimate guide to lung research tools and protocols eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in